AI Article Synopsis
- An ideal treatment for symptomatic Benign Prostatic Hyperplasia (BPH) should relieve lower urinary tract symptoms (LUTS) and improve Quality of Life (QoL), but current treatments often have negative side effects.
- Prostatic urethral lift (PUL) is a new endourology procedure that effectively alleviates LUTS without those adverse effects on QoL.
- Research shows PUL is a viable option for patients with small to medium-sized prostates (< 80 ml), particularly those who haven’t responded to medical therapies or cannot tolerate them, and who want to maintain sexual function.
Article Abstract
An ideal treatment option for symptomatic Benign Prostatic Hyperplasia (BPH) should relieve lower urinary tract symptoms (LUTS) and restore Quality of Life (QoL). Currently available medical therapies and surgical options for symptomatic BPH have side effects that adversely affects quality of life. Prostatic urethral lift (PUL) is a novel endourology procedure that promises to relieve LUTS without the aforementioned side effects. Areas covered: We diligently reviewed all the published literature on PUL, till July 2016 using standard search criteria. Expert commentary: There is good quality evidence to establish the efficiency of PUL in treating symptomatic BPH without adversely affecting the QoL. Based on the current literature, PUL can be considered as an option for those symptomatic BPH patients with small or medium size prostates (< 80 ml) without median lobe enlargement, who failed on medical therapy or are intolerant to it and wish to preserve their sexual function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17434440.2017.1296762 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Water vapor thermal therapy for treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia (≥ 80 g).
World J Urol
January 2025
Department of Urology, AP-HM, North Hospital, Marseille, France.
Introduction: Water vapor thermal therapy (WVTT; REZUM™; Boston, USA) offers symptom relief with reduced risks of complications in patients with lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). WVTT therapy has been validated in the pivotal study in men with smaller prostates (< 80 cc). Yet, its feasibility for larger prostates (≥ 80 cc) remains underexplored.
View Article and Find Full Text PDFBenign prostatic hyperplasia (BPH) is among the most common age-associated diseases in men; however, the contribution of age-related changes in immune cells to BPH is not clear. The current study determined that an age-associated CD8 T cell subset (Taa) with high Granzyme K ( ) and low Granzyme B ( ) gene expression infiltrate aged human prostates and positively correlate with International Prostate Symptom Score (IPSS). A velocity analysis indicated that CD8 T cell differentiation is altered in large BPH prostates compared to small age-matched prostates, favoring Taa accumulation.
View Article and Find Full Text PDFHemostasis is a critical aspect of holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH). While HoLEP offers superior outcomes compared to traditional techniques, effective intraoperative and postoperative bleeding control remains a challenge. This report evaluates the feasibility and safety of PuraBond® (3-D Matrix, Ltd.
View Article and Find Full Text PDFSafety and Clinical Efficacy of Prostatic Artery Embolization in Patients with Indwelling Urinary Catheter for Benign Hyperplasia-A Multicenter Study.
Diagnostics (Basel)
December 2024
Service de Radiologie et Imagerie Médicale de L'adulte, Centre Hospitalier Universitaire de Bordeaux, Place Amélie Raba Léon, 33076 Bordeaux, France.
: This multicentric study aimed to evaluate the efficacy and safety of prostatic artery embolization (PAE) to remove indwelling urinary catheter (IUC) in patients with symptomatic benign prostatic hyperplasia (BPH). Secondary objectives were to identify features associated with post-PAE catheter-free survival (PCFS). : All consecutive patients who underwent PAE for IUC related to BPH with a follow-up of at least 2 years (except for early death) in 6 French University Hospitals were retrospectively included.
View Article and Find Full Text PDFNon-surgical management of BPH: An updated review of current literature and state of the art on natural compounds and medical therapy.
Arch Ital Urol Androl
December 2024
Casa di Cura Musumeci-Gecas, 95030 Gravina di Catania.
Introduction: Benign prostatic hyperplasia (BPH) is a common urological disease that is strongly associated with the aging process and can lead to lower urinary tract symptoms (LUTS). LUTS due to BPH can significantly affect the quality of life of many patients. Among the treatments available for BPH to improve symptoms and functional outcomes, drug therapy and surgical therapy are the options of choice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!